Arian Chehrehsa, DDS
Oral and Maxillofacial Surgery · Gilroy, CANPI 1992145395
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,500 of the $8,821 with a category attached, or 85.0%. Nobel Biocare USA accounts for 95.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $7,648 and has fallen 95.6% since, to $334 in 2025. Among oral and maxillofacial surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $588.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nobel Biocare USA$8K
- Straumann USA LLC$334
- Zimvie Inc.$32
- Orapharma, A Division Of Bausch Health US, LLC$12
What the payments were for
- Speaking & faculty fees$7,50085%
- Food & beverage$4265%
- Education$89510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nobel Biocare USA | 6 | $8,444 |
| Straumann USA LLC | 7 | $334 |
| Zimvie Inc. | 1 | $32 |
| Orapharma, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EDUCATION$7,500
- NOBELPARALLEL$795
- NOBELACTIVE$795
How this compares
$8,821 in reported general payments places this provider in the 90th percentile of 941 oral and maxillofacial surgery providers in California.
See all oral and maxillofacial surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Chlorhexidine Gluconate | 84 | $521 |
| Penicillin V Potassium | 83 | $406 |
| Ibuprofen | 71 | $314 |
| Amoxicillin | 26 | $82 |
| Azithromycin | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Other oral and maxillofacial surgery in Gilroy
- Edmond BedrossianSan Francisco$3.7M
- Peter WohrleNewport Beach$735K
- Jone KimBrea$721K
- G William ArnettSanta Barbara$713K
- Arshiya SharafiSan Diego$457K
- Alan HerfordColton$292K
- Robert HaleWoodland Hills$230K
- Tara AghalooLos Angeles$214K
- Daniel HammerSan Diego$201K
- Nader SalibMission Viejo$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.